Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Avonex · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Active treatment | EXPERIMENTAL | Interferon treatment for MS |
| Avonex | EXPERIMENTAL | 4 weekly injections of Avonex (IM) |
| Group 1 | EXPERIMENTAL | No dose titration |
| Group 2 | EXPERIMENTAL | Fast dose titration |
| Group 3 | EXPERIMENTAL | Slow dose titration |
| Name | Type | Description |
|---|---|---|
| Avonex | DRUG | Interferon treatment for MS |
Inclusion Criteria: * Ability to understand risks of study and provide informed consent. * Must be Chinese, aged 18 to 55 years inclusive at time of consent. * Must have diagnosis of relapsing MS of 3 months duration at time of screening visit. * Must have at least 1 documented MS attack within 3 y...
Avonex is used for the treatment of relapsing multiple sclerosis (MS). It has been studied in Chinese subjects with relapsing MS to evaluate its safety and tolerability. Avonex is also being investigated in healthy volunteers to assess its effects, including the incidence of flu-like symptoms and its pharmacokinetic and pharmacodynamic profile.
Avonex is developed by Biogen Inc., a biotechnology company listed on the NASDAQ under the ticker symbol BIIB. Biogen is responsible for the clinical development and commercialization of Avonex.
Avonex is in clinical development. It has completed Phase 1 trials in healthy volunteers, including a study on dose titration and a pharmacokinetic study in Chinese subjects. It has also completed a Phase 3 trial in Chinese subjects with relapsing multiple sclerosis.
Avonex has been studied in several completed clinical trials. NCT01119677 is a Phase 1 study in healthy volunteers examining dose titration effects on flu-like symptoms. NCT01181115 is a Phase 3 safety and tolerability study in Chinese subjects with relapsing MS. NCT01416207 is a Phase 1 pharmacokinetic and pharmacodynamic study in Chinese healthy volunteers.
Avonex is a specific drug product developed by Biogen Inc. It is not referred to by any alternative names in the clinical trial records. The trials listed for Avonex use the name Avonex exclusively.